The Role of Line-Field Confocal Optical Coherence Tomography in Detecting Extramammary Paget Disease Recurrences: A Pilot Diagnostic Study.

Autor: Diet G; Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium., Lenoir C; Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium.; Melanoma Unit, Hospital Clinic Barcelona, University of Barcelona, 08036 Barcelona, Spain., Fontaine M; Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium., Boussingault L; Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium.; Department of Dermatology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium., Orte Cano C; Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium.; Department of Dermatology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium., Mtimet L; Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium., Liénard D; Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium.; Department of Dermatology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium., Sanak D; Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium., Moulart F; Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium., Bernardi D; Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium., Trepant AL; Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium., Perez-Anker J; Melanoma Unit, Hospital Clinic Barcelona, University of Barcelona, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Carlos III Health Institute, 28029 Barcelona, Spain., Puig S; Melanoma Unit, Hospital Clinic Barcelona, University of Barcelona, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Carlos III Health Institute, 28029 Barcelona, Spain., Malvehy J; Melanoma Unit, Hospital Clinic Barcelona, University of Barcelona, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Carlos III Health Institute, 28029 Barcelona, Spain., Cinotti E; Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.; Groupe d'Imagerie Cutanée Non Invasive (GICNI) of the Société Française de Dermatologie (SFD), 42055 Paris, France., Tognetti L; Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy., Rubegni P; Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy., Perrot JL; Department of Dermatology, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France., Marmol VD; Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium.; Department of Dermatology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium., Suppa M; Department of Dermatology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium.; Groupe d'Imagerie Cutanée Non Invasive (GICNI) of the Société Française de Dermatologie (SFD), 42055 Paris, France.

Publikováno v: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2024 Jul 19; Vol. 14 (14). Date of Electronic Publication: 2024 Jul 19.

Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: A corollary study to EORTC trial 18952

Autor: Bouwhuis, M.G., Suciu, S., Kruit, W., Salès, F., Stoitchkov, K., Patel, P., Cocquyt, V., Thomas, J., Liénard, D., Eggermont, A.M.M., Ghanem, G.

Publikováno v: In European Journal of Cancer February 2011 47(3):361-368

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group

Autor: Punt, C.J.A., Suciu, S., Gore, M.A., Koller, J., Kruit, W.H.J., Thomas, J., Patel, P., Lienard, D., Eggermont, A.M.M., Keilholz, U.

Publikováno v: In European Journal of Cancer 2006 42(17):2991-2995

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin

Autor: Keilholz, U., Martus, P., Punt, C.J.A., Kruit, W., Mooser, G., Schadendorf, D., Liénard, D., Dummer, R., Koller, J., Voit, C., Eggermont, A.M.M.

Publikováno v: In European Journal of Cancer 2002 38(11):1501-1511

Recognition of tumor-associated antigens by T-lymphocytes: Perspectives for peptide-based vaccines

Autor: Cerottini, J.-C, Liénard, D., Romero, P.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______805::6c042b6c6d3e44427550f2c804d97e9a
http://doc.rero.ch/record/298212/files/7-4-339.pdf